1. Signaling Pathways
  2. GPCR/G Protein
  3. Prostaglandin Receptor
  4. Prostaglandin Receptor Agonist

Prostaglandin Receptor Agonist

Prostaglandin Receptor Agonists (156):

Cat. No. Product Name Effect Purity
  • HY-108415R
    Cloprostenol sodium salt (Standard)
    Agonist
    Cloprostenol sodium salt (Standard) is the analytical standard of Cloprostenol sodium salt. This product is intended for research and analytical applications. Cloprostenol sodium salt (ICI 80996 sodium salt) is a potent synthetic prostaglandin analogue, acts as a luteolytic agent, and is a PGF2α receptor agonist.
  • HY-130395
    15-Keto latanoprost
    Agonist
    15-Keto latanoprost is a metabolite of Latanoprost, which is an ocular hypotensive agent.
  • HY-14839A
    Evatanepag sodium
    Agonist
    Evatanepag sodium is a non-prostanoid, potent and selective EP2 receptor agonist. Evatanepag sodium can induce local bone formation in vivo. Evatanepag sodium can be used in the research of fractures, bone defects, asthma.
  • HY-168978
    Irodanoprost
    Agonist
    Irodanoprost is the agonist for prostaglandin receptor that can be used for research of osteogenesis-related diseases.
  • HY-100441S3
    Treprostinil-d7
    Agonist
    Treprostinil-d7 (UT-15-d7) is a deuterated version of Treprostinil (HY-100441). Treprostinil is a highly potent DP1 and EP2 agonist with EC50s of 0.6 nM and 6.2 nM, respectively.
  • HY-118190
    AL 8810 methyl ester
    Agonist
    AL 8810 methyl ester is a prostaglandin F(2α) analog and a prostaglandin F(2α) receptor agonist. Can competitively antagonize the effects of the FP receptor agonist Fluprostenol (HY-108560). AL 8810 methyl ester has no significant potency against TP, DP, EP(2), EP(4) receptor subtypes in cell lines.
  • HY-135023
    5-trans-PGE2
    Agonist
    5-trans-PGE2 (5-trans Prostaglandin E2) is the active isomer of PGE2 and a potent activator of aromatase. Supplements the process of paracrine signaling between epithelial cells (expressing high levels of PGE2) and surrounding stromal cells (expressing high levels of aromatase). This process is involved in the growth and development of breast cancer.
  • HY-12956S1
    Dinoprost-d9
    Agonist
    Dinoprost-d9 is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour.
  • HY-124363
    5-cis Carbaprostacyclin
    Agonist
    5-cis Carbaprostacyclin is a stable analog of PGI2 based on Carbaprostacyclin (HY-112322). Carbacyclin is a PGI2 receptor agonist and vasodilator that activates PPARδ. 5-cis Carbaprostacyclin induces relaxation of pulmonary vascular tone.
  • HY-107381A
    (+)-Cloprostenol sodium
    Agonist
    (+)-Cloprostenol sodium is a prostaglandin F2α (PGF2α) analogue, and shows selective agonistic activity at the prostaglandin receptor.
  • HY-14870S3
    Selexipag-d6
    Agonist
    Selexipag-d6 is deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).
  • HY-122147
    L-644698
    Agonist
    L-644698 is a potent and selective human recombinant prostaglandin D2 (PGD2) receptor (hDP) agonist with Ki values of 0.9, 267, 3730, 9280 nM for hDP, hEP2, hEP3, hEP4, respectively. L-644698 induces cyclic AMP production with an EC50 value of 0.5 nM.
  • HY-106054
    Nocloprost
    Agonist
    Nocloprost, a prostaglandin E2 (PGE2) analog, is an orally active EP1- and EP3-receptor agonist. Nocloprost inhibits evoked [3H]ACh release. Nocloprost has gastroprotective and ulcer-healing properties. Nocloprost accelerates the healing of chronic gastric ulcerations and enhances mucosal growth in rats.
  • HY-172099
    EP4 receptor agonist 3
    Agonist
    EP4 receptor agonist 3 is an EP4 receptor agonist that can be used in the study of colitis models in mice with DSS.
  • HY-138868
    17-Phenyl trinor prostaglandin E2 ethyl amide
    Agonist
    17-Phenyl trinor prostaglandin E2 ethyl amide (17-Phenyl trinor PGE2 ethyl amide) is a EP1 receptor agonist. 17-Phenyl trinor prostaglandin E2 ethyl amide aggravates renal dysfunction and glomerulosclerosis.
  • HY-B0584R
    Travoprost (Standard)
    Agonist
    Travoprost (Standard) is the analytical standard of Travoprost. This product is intended for research and analytical applications. Travoprost (Fluprostenol isopropyl ester), an isopropyl ester proagent, is a high affinity, selective FP prostaglandin full receptor agonist. Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension.
  • HY-139386
    15β-Travoprost
    Agonist
    15β-Travoprost (15(S)-Flu-Ipr) is an enantiomer of Travoprost (HY-B0584). Travoprost, an isopropyl ester proagent, is a high affinity, selective FP prostaglandin full receptor agonist.
  • HY-N6070AR
    Ricinoleic acid (purity≥99%) (Standard)
    Agonist
    Ricinoleic acid (purity≥99%) (Standard) is the analytical standard of Ricinoleic acid (purity≥99%). This product is intended for research and analytical applications. Ricinoleic acid (purity≥99%), a hydroxy fatty acid, is an attractive feedstock for the production of high-performance lubricants, cosmetics, polymers, surfactants, and coatings. Ricinoleic acid is the main active ingredient of Castor oil (HY-107799). Ricinoleic acid is the agonist for prostaglandin EP3 receptor (EP3 receptor) (EC50 in MEG-01 is 0.5 μM), that causes laxative effects and uterine contraction. Ricinoleic acid exhibits antianxiety-like, anti-inflammatory and pro-inflammatory properties.
  • HY-137483
    Prostaglandin D2 serinol amide
    Agonist
    Prostaglandin D2 serinol amide is a weak inhibitor of the hydrolysis of [3H]2-oleoylglycerol.
  • HY-116431
    I-BOP
    Agonist
    I-BOP is an agonist for thromboxane A2 receptor (TP) with a KD of 0.61 nM. I-BOP promotes proliferation through activation of PI3K pathway in vascular smooth muscle. I-BOP dose-dependently biphasicly affects the excitatory postsynaptic potential (e.p.s.p.) in hippocampal neurons.